FDA Clears 31 New Molecular Entities In 2004, Up Ten From Previous Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's Lyrica (pregabalin) is the final NME of the year. Over 20% of the approvals came in the last two weeks of December.
You may also be interested in...
Prialt Sales Sluggish, But Elan Expects Rapid Growth
Additional audiences for the pain product are being targeted following a "quiet" launch at the beginning of the year.
Prialt Sales Sluggish, But Elan Expects Rapid Growth
Additional audiences for the pain product are being targeted following a "quiet" launch at the beginning of the year.
Average Approval Time Slows As FDA Clears Greater Number Of NMEs In 2004
Average time to approval was 18.7 months for a new molecular entity in 2004, versus 17.1 in 2003. FDA cleared 31 NMEs in 2004, 10 more than the prior year. CDER appears to be setting a strong precedent with its first year of therapeutic biologic reviews.